Effect of glucagon-like peptide-1 receptor agonists on respiratory drive in patients with obesity and type 2 diabetes: a retrospective case-control study of the SOON cohort

Extract GLP-1 receptor agonists (GLP-1RAs) have been used for around twenty years in the treatment of type 2 diabetes. Extensive research programs have since evaluated the effect of higher doses to repurpose these molecules in the treatment of obesity and its complications. The observed effects on weight loss range from −6% to −20% of total body weight, depending on the molecules studied. Through this weight loss, but also likely via other processes, GLP-1RAs protect renal function, improve metabolic associated steato-hepatitis (MASH), heart failure and knee osteoarthritis, and reduce the risk of cardiovascular events [1].

Authors

Institutions

Publication Details

Journal
ERJ Open Research
Published
2026-11-19
DOI
https://doi.org/10.1183/23120541.01236-2026
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effect of glucagon-like peptide-1 receptor agonists on respiratory drive in patients with obesity and type 2 diabetes: a retrospective case-control study of the SOON cohort

Matthieu Roustit, Sam Bayat, Anne‐Laure Borel, Mathilde Quema
ERJ Open Research
Diabetes Treatment and Management
article

Effect of glucagon-like peptide-1 receptor agonists on respiratory drive in patients with obesity and type 2 diabetes: a retrospective case-control study of the SOON cohort

Matthieu Roustit, Sam Bayat, Anne‐Laure Borel, Mathilde Quema
article en

Abstract

Extract GLP-1 receptor agonists (GLP-1RAs) have been used for around twenty years in the treatment of type 2 diabetes. Extensive research programs have since evaluated the effect of higher doses to repurpose these molecules in the treatment of obesity and its complications. The observed effects on weight loss range from −6% to −20% of total body weight, depending on the molecules studied. Through this weight loss, but also likely via other processes, GLP-1RAs protect renal function, improve metabolic associated steato-hepatitis (MASH), heart failure and knee osteoarthritis, and reduce the risk of cardiovascular events [1].

ERJ Open Research
Inserm (FR), Centre Hospitalier Universitaire de Grenoble (FR), Université Grenoble Alpes (FR)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon